Precigen (PGEN) Capital Expenditures (2012 - 2026)
Precigen (PGEN) posted quarterly Capital Expenditures of $198000.0 for Q1 2026, down 68.17% year-over-year from $622000.0 in Q1 2025, and up 1000.0% quarter-over-quarter from $18000.0 in Q4 2025.
Powered by 
Analysis
Precigen (PGEN) Capital Expenditures (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Capital Expenditures for 15 consecutive years, with $198000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 68.17% year-over-year to $198000.0; the TTM figure through Mar 2026 stood at $1.6 million (up 146.37% YoY), while the FY2025 annual figure was $2.0 million, up 485.04% from the prior year.
- Capital Expenditures rose to $198000.0 in Q1 2026 per PGEN's latest filing, from $18000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $4.6 million in Q3 2022 and bottomed at -$7.2 million in Q4 2024.
- Historically, Capital Expenditures has averaged $472000.0 across 5 years, with a median of $231000.0 in 2023.
- On a YoY basis, Capital Expenditures climbed as much as 18029.17% in 2024 and fell as far as 9720.0% in 2024.
- Precigen's Capital Expenditures stood at $53000.0 in 2022, then jumped by 41.51% to $75000.0 in 2023, then slumped by 9720.0% to -$7.2 million in 2024, then soared by 100.25% to $18000.0 in 2025, then jumped by 1000.0% to $198000.0 in 2026.
- Business Quant data shows PGEN's Capital Expenditures at $198000.0 in Q1 2026, $18000.0 in Q4 2025, and $1.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | 392,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 392,000.00 |
| Mar 31, 2026 | 258,000.00 |
| Dec 31, 2025 | 18,000.00 |
| Sep 30, 2025 | 389,000.00 |
| Jun 30, 2025 | 722,000.00 |
| Mar 31, 2025 | 866,000.00 |
| Dec 31, 2024 | 1.03 Mn |
| Sep 30, 2024 | 882,000.00 |
| Jun 30, 2024 | 2.32 Mn |
| Mar 31, 2024 | 4.35 Mn |
| Dec 31, 2023 | 764,000.00 |
| Sep 30, 2023 | 517,000.00 |
| Jun 30, 2023 | 101,000.00 |
| Mar 31, 2023 | 154,000.00 |
| Dec 31, 2022 | 53,000.00 |
| Sep 30, 2022 | 1.57 Mn |
| Jun 30, 2022 | 1.72 Mn |
| Mar 31, 2022 | 1.58 Mn |
| Dec 31, 2021 | 2.77 Mn |
| Sep 30, 2021 | 2.27 Mn |